Hospital
North Shore Medical Center, INC.
North Shore Medical Center, INC. was paid $2.52M by Medicaid between Jan 2018 and Nov 2021, across 137 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 16% of everything it billed.
33Billing provider infoNORTH SHORE MEDICAL CENTER, INC.
LAUDERDALE LAKES, FL 33313
LAUDERDALE LAKES, FL 33313
33aNPI1255572228assigned 03/20/2009
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.52M
24GClaims256,085
24DCodes billed137
24AFirst – last monthJan 2018 – Nov 2021
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#111 of 163
Median peer was paid$4.77M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,343 | $445K | |
| 2019 | 95,837 | $885K | |
| 2020 | 67,448 | $683K | |
| 2021 | 53,457 | $510K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 16% | 13,299 | 8,558 | $411K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.2% | 10,555 | 7,861 | $232K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.0% | 8,818 | 6,854 | $228K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.8% | 3,796 | 2,510 | $147K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 6,454 | 4,914 | $119K |
| G0378 | Hospital observation service, per hour | 4.0% | 8,334 | 2,598 | $101K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.7% | 5,494 | 3,054 | $93K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.5% | 2,822 | 1,958 | $89K |
| S0028 | Injection, famotidine, 20 mg | 3.5% | 1,119 | 808 | $89K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 1,596 | 1,415 | $69K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.5% | 1,068 | 760 | $63K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 2,612 | 1,913 | $59K |
125 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 2.3% | 3,695 | $58K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 2.2% | 3,220 | $55K |
| 81001 | 2.0% | 7,537 | $49K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 2,968 | $48K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 1.7% | 2,503 | $44K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 1,470 | $37K |
| 81025 | 1.3% | 5,893 | $33K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 877 | $30K |
| 36415 | Collection of venous blood by venipuncture | 1.0% | 2,327 | $26K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,429 | $24K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,121 | $24K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,813 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,813 | $23K |
| 82962 | <1% | 7,468 | $23K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 687 | $22K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,849 | $21K |
| J3490 | Unclassified drugs | <1% | 279 | $19K |
| J1815 | Injection, insulin, per 5 units | <1% | 828 | $18K |
| A9270 | Non-covered item or service | <1% | 5,173 | $14K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,861 | $14K |
| 84484 | <1% | 6,318 | $12K | |
| 97162 | <1% | 817 | $12K | |
| 87070 | <1% | 1,795 | $12K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,748 | $11K |
| 96376 | <1% | 2,917 | $11K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,678 | $9K |
| 85610 | <1% | 4,832 | $9K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,162 | $9K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,031 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,653 | $8K |
| 85730 | <1% | 4,399 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,496 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,944 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 250 | $5K |
| 74018 | <1% | 1,222 | $5K | |
| 83735 | <1% | 2,692 | $5K | |
| 76801 | <1% | 466 | $5K | |
| 87081 | <1% | 2,261 | $5K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 874 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,499 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 526 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 878 | $3K |
| 83690 | <1% | 2,690 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 554 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,717 | $3K |
| 83880 | <1% | 1,647 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 186 | $3K |
| 84702 | <1% | 2,122 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 566 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 85 | $2K |
| 85027 | <1% | 1,327 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,698 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,300 | $2K |
| 87040 | <1% | 1,648 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,908 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 936 | $1K |
| 87077 | <1% | 1,495 | $1K | |
| 97116 | <1% | 293 | $1K | |
| 87186 | <1% | 1,449 | $1K | |
| 72100 | <1% | 67 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,602 | $1K |
| 84100 | <1% | 668 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,179 | $1K |
| A4217 | Sterile water/saline, 500 ml | <1% | 169 | $961.69 |
| 86850 | <1% | 761 | $943.35 | |
| 73030 | <1% | 32 | $887.65 | |
| 82550 | <1% | 1,670 | $877.16 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,261 | $838.98 |
| 85379 | <1% | 793 | $802.49 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 998 | $772.15 |
| 73610 | <1% | 56 | $757.18 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 173 | $732.05 |
| 93971 | <1% | 49 | $714.78 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 97 | $637.83 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 67 | $611.80 |
| 87430 | <1% | 741 | $582.23 | |
| 73564 | <1% | 97 | $581.93 | |
| 86900 | <1% | 789 | $559.64 | |
| 80061 | Lipid panel | <1% | 91 | $501.29 |
| 87205 | <1% | 1,111 | $439.84 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 809 | $433.56 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 446 | $353.35 |
| 86901 | <1% | 787 | $326.35 | |
| 29125 | <1% | 14 | $310.87 | |
| 93970 | <1% | 50 | $263.85 | |
| 83605 | <1% | 495 | $263.22 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 31 | $251.05 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 438 | $243.18 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 349 | $241.91 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 58 | $213.48 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 19 | $208.33 |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 13 | $192.73 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 191 | $191.80 |
| 73630 | <1% | 49 | $182.83 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 105 | $146.12 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 79 | $139.24 |
| 99001 | <1% | 121 | $138.41 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 79 | $103.07 |
| 85045 | <1% | 251 | $101.63 | |
| 83615 | <1% | 57 | $98.60 | |
| 90714 | <1% | 124 | $92.12 | |
| 72170 | <1% | 16 | $77.76 | |
| 87810 | <1% | 394 | $77.02 | |
| 87400 | <1% | 74 | $68.90 | |
| 87808 | <1% | 467 | $66.15 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 177 | $23.21 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 17 | $21.14 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 210 | $17.00 |
| 86140 | <1% | 87 | $9.61 | |
| 87185 | <1% | 16 | $4.47 | |
| 85651 | <1% | 78 | $4.32 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 43 | $3.44 |
| 80076 | <1% | 43 | $3.17 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 179 | $2.23 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 28 | $1.86 |
| 73130 | <1% | 18 | $1.24 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14 | $0.55 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 12 | $0.55 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 85 | $0.00 |
| 84439 | 0% | 46 | $0.00 | |
| 99218 | 0% | 72 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 22 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 33 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 15 | $0.00 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialARMIN, CRAIG (VP OF GOVT PROGRAMS, TENET)
| Provider | Location | Paid |
|---|---|---|
| Lifemark Hospitals of Florida, INC. | Hialeah, FL | $7.11M |
| North Shore Medical Center, INC. | Miami, FL | $4.42M |
| Hialeah Hospital INC. | Hialeah, FL | $3.62M |
| CGH Hospital, LTD. | Coral Gables, FL | $1.67M |
| VHS West Suburban Medical Center INC | Oak Park, IL | $1.46M |
| VHS Westlake Hospital INC | Melrose Park, IL | $326K |
| Tenet Healthsystem ST. Christopher's Hospital for Children, LLC | Philadelphia, PA | $22K |
| FMC Hospital, LTD. | Lauderdale Lakes, FL | $4K |
| San Dimas Community Hospital, INC. | San Dimas, CA | $963.01 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.